- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02770508
Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)
A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Key Inclusion Criteria
- Documented HIV RNA >1000 copies/ml
- Subject naïve to ARV. .
- Subject has indication to receive an antiretroviral regimen, based on local guidelines.
- Able to provide informed consent and agree to use a highly effective non-hormonal method of contraception
Key Exclusion Criteria
- Evidence of resistance to Darunavir and/or FTC or 3TC or TDF based on the resistance test
- Patient with chronic hepatitis B
- Subject has a currently active AIDS defining illness (Category C conditions according to the CDC Classification System
- Required use of disallowed concomitant therapies
- Subject with the grade 3 or 4 laboratory abnormalities as defined by DAIDS grading table
Primary Objective
• Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at week 48 (ITT analysis, Snapshot analysis)
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, 1121
- Consultorio Infectológico Dr. Pryluka
-
Caba, Buenos Aires, Argentina, 1155ADP
- Hospital Cosme Argerich
-
Caba, Buenos Aires, Argentina, 1199ABB
- Hospital Italiano
-
Caba, Buenos Aires, Argentina, C1202ABB
- Fundación Huésped
-
Caba, Buenos Aires, Argentina, C1425AWK
- Centro de Estudios Infectologicos SA (CTD Stamboulian)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- > 18 years of age.
- Patient with documented HIV-1 infection defined as a positive ELISA plus a confirmatory Western Blot; or alternatively, a plasma HIV-1 RNA ≥1,000 copies/mL ever documented.
- Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.
- Subject agrees not to take any medication during the study, including over the counter medicines or herbal preparations, without the approval of the trial physician.
- Documented HIV-1 RNA >1,000 copies/mL
- Subject naïve to ARV. (Patients who had received ARV ≤ 48 hours are allowed). Subject has indication to receive an antiretroviral regimen.
- Subjects can comply with protocol requirements.
- Subject's general medical condition, in the investigator's opinion, does not interfere with assessments and completion of the trial.
If patient is a female she must not be breastfeeding or pregnant. She must be either postmenopausal for at least one year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or she must:
- use 2 different methods of birth control including, at least, one barrier method, and are acceptable to both the subject and investigator, and
- has a urine pregnancy test performed at the Screening Visit and on Baseline. Results of both tests must be negative.
- continue using 2 different methods of birth control including, at least, one barrier method for at least 30 days after the end of the treatment period
- For male patients, must comply with the use of a barrier birth control method during the Study and 60 days beyond the Study completion
Exclusion criteria :
Evidence of resistance to or 3TC or DRV/r, TDF, FTC o 3TC based in the results of the resistance testing done in the screening visit, such resistance being considered in accordance with IAS-USA panel, version dated March 2013.
Any of the following mutations will be considered resistance to DRV/r :
- I47V, I50V, I54M/L, L76V, I84V or, 3 or more minor mutations : V11I, V32I, L33F, T74P, L89V.
- Any of the following mutations will be considered resistance to 3TC or FTC : M184V/I and /or K65R and / or Q151M.
- Any of the following mutations will be considered resistance to TDF: K65R, K70E, double insertion 69 or 3 TAMS including M41L or L210W.
- Prior HIV-2 documented infection.
- The use of disallowed concomitant therapy (see Appendix C).
- Active Hepatitis B infection (at any stage).
- The patient was diagnosed with acute active hepatitis by any cause, or chronic hepatitis C WITH levels of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 5 higher than the upper limit of normal (ULN) AND/OR may require one-year treatment.
- Any clinical significant active disease (for instance, tuberculosis, heart failure, pancreatitis) or any medical history or physical examination findings that, according to the investigator's opinion, may risk the patient's safety, the results of the study or adherence to the rules of the protocol.
- The patient has an active AIDS-associated opportunistic disease (Category C according to the CDC classification system for HIV infection as of 1993) within 30 days after the screening. Stabilized patients under treatment for AIDS-associated opportunistic disease may be included in the study.
- Life expectancy < 1 year according to the investigator
Laboratory tests performed during the screening visit show any of the following alterations:
- Hemoglobin <8.0 gm/dL
- Absolute neutrophil count (ANC) < 750 cells/µL
- Platelet Count < 50,000 cells/mm3
- The use of any study agent within 30 days as from the screening.
- Use of immunosuppressive drugs, cytokines inhibitors or other cytokines over the prior year.
- Any other condition (including, without limitation, the use of alcohol or drugs) that in the investigator's opinion may compromise the safety of the patient or his/her adherence to the protocol
- Patients who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Darunavir/ritonavir plus lamivudine
Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
|
Other Names:
Other Names:
|
Active Comparator: Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)
Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with HIV-1 RNA levels of less than 50 copies/mL at week 48
Time Frame: 48 weeks
|
The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) <50 c/mL at Week 48 will be assessed using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.
This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with HIV-1 RNA <400 copies/mL at week 24
Time Frame: 24 weeks
|
The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) <400 c/mL at Week 24 will be assessed using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.
|
24 weeks
|
Number and type of resistance mutations in case of virologic failure
Time Frame: from week 24 to week 48
|
An genotiping test will be made at time to virological failure to detect mutation across reverse transcriptase (RT), and Protease (PRO).
Protocol defined virological failure was defined as confirmed plasma HIV-1 RNA levels >=400 copies/mL on or after Week 24 or confirmed plasma HIV-1 RNA levels >=50 copies/mL at week 48
|
from week 24 to week 48
|
CD4+ lymphocyte count and change between baseline (defined as the average between screening and baseline visit values) and weeks 24 and 48
Time Frame: week 24 and 48
|
Change from Baseline in CD4+ cell counts will be assessed at Weeks 24 and 48.
|
week 24 and 48
|
Frequency, type and severity of adverse events and laboratory abnormalities.
Time Frame: week 24 and 48
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
|
week 24 and 48
|
Clinical disease progression (CDP)
Time Frame: week 24 and 48
|
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system.
Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection.
CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition.
Indicators of CDP were defined as: CDC CAT A at Baseline (BS) to a CDC CAT C event (EV); CDC CAT B at BS to a CDC CAT C EV; CDC CAT C at BS to a new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.
|
week 24 and 48
|
Changes in quality of life
Time Frame: baseline, week 24 and week 48
|
The evaluation of quality of life will be done through two validated instruments: the Medical Outcomes Study HIV Health Survey ( MOS - HIV) and EuroQol 5D (EQ - 5D ) .
Both instruments will be administered to patients at baseline , week 24 and week 48 .
|
baseline, week 24 and week 48
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pedro Cahn, PhD, MD, Fundación Huésped
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Tenofovir
- Emtricitabine
- Ritonavir
- Lamivudine
- Darunavir
Other Study ID Numbers
- FH-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Lamivudine
-
Nanfang Hospital of Southern Medical UniversityGlaxoSmithKline; Major Science and Technology Special Project of China Eleventh...Completed
-
Glaxo WellcomeUnknownHIV InfectionsUnited States
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Puerto Rico, Costa Rica, Panama
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Korea UniversityGlaxoSmithKlineCompletedChronic Hepatitis BKorea, Republic of
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
-
Glaxo WellcomeCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
ViiV HealthcareSyneos HealthTerminatedHIV InfectionsGermany, Spain, United States, Canada, France, Italy, South Africa, Argentina, Portugal, Puerto Rico